ArticleBioengineering & translational medicine2026
Extracellular vesicles from glucocorticoids-preconditioned synovial mesenchymal stem cells exert antiarthritic effects by downregulating the mRNA m6A modification of NLRP3 in macrophages through miR-212-5p.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metformin-pretreated synovial mesenchymal stem cell-derived exosomes alleviate osteoarthritis via the miR-1208/METTL3/NLRP3 axis.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a prevalent chronic degenerative joint disease with no known treatment for reversing its progression. However, recent studies have shown promising results for nano-sized extracellular vesicles derived from preconditioned synovial mesenchymal stem cells (SMSCs) in treating various diseases, including OA. Glucocorticoids (GCs) possess potent anti-inflammatory properties, but their long-term use is limited due to potential adverse reactions. Building on previous research, this study aimed to investigate the therapeutic potential of extracellular vesicles secreted from GCs-pretreated SMSCs (GCs-EVs) in exerting antiarthritic effects. The results demonstrated that GCs-EVs effectively inhibited cartilage degeneration and osteophyte formation in the OA mouse model by suppressing the release of inflammatory cytokines from synovial macrophages. This effect was attributed to the high expression of miR-212-5p in GCs-EVs, which specifically inhibited the expression of methyltransferase-like 3 (Mettl3). Consequently, the mRNA N6-methyladenosine (m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.